$15.72
2.66% day before yesterday
NYSE, Sep 06, 10:10 pm CET
ISIN
US03969F1093
Symbol
RCUS
Sector
Industry

Arcus Biosciences Stock price

$15.72
+1.24 8.56% 1M
-3.64 18.80% 6M
-3.38 17.70% YTD
-6.78 30.13% 1Y
-17.70 52.96% 3Y
+8.11 106.57% 5Y
-1.28 7.53% 10Y
NYSE, Closing price Fri, Sep 06 2024
-0.43 2.66%
ISIN
US03969F1093
Symbol
RCUS
Sector
Industry

Key metrics

Market capitalization $1.44b
Enterprise Value $479.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.94
P/S ratio (TTM) P/S ratio 5.82
P/B ratio (TTM) P/B ratio 2.26
Revenue growth (TTM) Revenue growth 103.73%
Revenue (TTM) Revenue $247.00m
EBIT (operating result TTM) EBIT $-273.00m
Free Cash Flow (TTM) Free Cash Flow $-267.00m
Cash position $969.00m
EPS (TTM) EPS $-3.10
P/E forward negative
P/S forward 5.30
EV/Sales forward 1.77
Short interest 15.74%
Show more

Is Arcus Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Arcus Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Arcus Biosciences forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Arcus Biosciences forecast:

Buy
80%
Hold
20%

Financial data from Arcus Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
247 247
104% 104%
100%
- Direct Costs 13 13
14% 14%
5%
234 234
120% 120%
95%
- Selling and Administrative Expenses 95 95
16% 16%
38%
- Research and Development Expense 399 399
24% 24%
162%
-260 -260
13% 13%
-105%
- Depreciation and Amortization 13 13
14% 14%
5%
EBIT (Operating Income) EBIT -273 -273
13% 13%
-111%
Net Profit -249 -249
13% 13%
-101%

In millions USD.

Don't miss a Thing! We will send you all news about Arcus Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcus Biosciences Stock News

Neutral
Business Wire
12 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,100 shares of the Company's comm...
Neutral
Business Wire
17 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Wednesday...
Positive
Seeking Alpha
29 days ago
Domvanalimab shows promising results in gastric cancer, with a 56% response rate and median progression-free survival of 12.9 months. Quemlicustat sees progress with Taiho exercising rights in Asia, while etrumadenant shows positive results in colorectal cancer trials. Arcus Biosciences pipeline continues to show potential, but TIGIT failures in the industry pose a significant risk to the compa...
More Arcus Biosciences News

Company Profile

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Head office United States
CEO Terry Rosen
Employees 577
Founded 2015
Website www.arcusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today